The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Seems like Tils planning for a massive future. As we all know, it's good to plan ahead.
Regeneron Pharmaceuticals, Inc., was only a $3billion market capitalisation company when he joined in 2010. I wonder what Tils MC be in 10 years time.
https://www.dailymail.co.uk/money/investing/article-9106815/Our-share-tips-New-Year-lets-hope-better-one.html
Alex Lawson, Senior City Correspondent
Amryt Pharma: Irish biotechnology firm Amryt has seen its share price double since March as investors piled into pharmaceutical stocks amid the Covid crisis. That trend shows little sign of abating. Amryt develops treatments for rare diseases and is trying to tackle 'butterfly skin' conditions, where the skin blisters easily.
It is awaiting regulatory approval for a promising cream that accelerates wound healing and reduces itching, and has just won US state support to study the genetics of the cause of the condition.
The company, listed on AIM in the UK and Nasdaq in America, recently raised $40million (£30million) in a share placing, so has the firepower to invest for growth. Its shares are currently at £1.89, valuing it at £335million. Far from a safe bet, but a promising prospect.
myboycasey, I appreciate you posting the RNS.
No wonder CF couldn't sit still during the interview last night, he knew what was coming and was trying to stop himself from talking about the contracts outside of an Rns
Link
https://www.google.com/amp/s/in.mobile.reuters.com/article/amp/idINKBN2710R2
Swapleber, you asked "One question...what are Mr. Wildlife et al going to get from the deals???"
My answer would be, if you are working with a company and you know the huge opportunity that can be benefited in the long term from the work you are performing in that company and the company is listed on on the Stock Exchange, you would buy shares in that company and await the reward of that hard work. As Mr Wildlife is not a director in Orph there would be no need for informing the market. That just IMHO.
Trader_3,
It looks like you are teasing us shareholders with you valuation. Hope your "back of fag packet"valuation is correct.
Nice mention of hVivo, good positive press coverage.
Landmark strategy launched to cement UK’s position as global leader in genomics
Health and Social Care Secretary Matt
https://www.gov.uk/government/news/landmark-strategy-launched-to-cement-uks-position-as-global-leader-in-genomics
Surely anyone doing any serious research after reading these reports will see the name hVivo mentioned, an easy search on hVivo will see that hVivo is part of the Open Orphan family, ORPH is the share to own and keep until CF sells.
Brilliant RNS, Amyt is going up.
But some will!
Could this be good news for OO . With the testing OO are now doing with the MosaiQ COVID-19 Antibody machine, surely it will be able to identify patients able to provide the plasma required for the treatment.
CF is taking a well deserved break with his family to charge his batteries, before the busy period from August to December when all these deal will be happening and he will be creating plenty of value for shareholders including himself.
Could today be that day when Ophan open with some great news?
Thanks zebbo for all the time and effort you put in not only doing your research but also sharing you research with fellow board members, much appreciated.
COVID-19 human challenge studies, will soon be happening and OO will be well positioned to contribute.
Thanks you, capitalidea, for that link and pointing to the mention of Adrian Wildfire returning to OO by the main man CF.
to start at the University of Queensland in Australia on Monday. Could this be a sign that OO will soon start Human trials in the UK?